4+1 the right balance in Parkinson’s disease

Presentation
Madopar contains a combination of levodopa and the decarboxylase inhibitor benzerazide in the ratio of 4:1. Madopar 62.5 capsules containing 50mg levodopa and 14.25mg benzerazide hydrochloride (equivalent to 12.5mg of the base) Madopar 125 capsules containing 100mg levodopa and 28.5mg benzerazide hydrochloride (equivalent to 25mg of the base) Madopar 250 capsules containing 200mg levodopa and 57mg benzerazide hydrochloride (equivalent to 50mg of the base).

Indications
Parkinsonism – idiopathic, post-encephalitic

Dosage
Dosage is variable and the data sheet should be consulted for full details. The effective daily dose usually lies between four and eight capsules of Madopar 125 (two to four capsules of Madopar 250) daily in divided doses. Most patients requiring no more than six capsules of Madopar 125 daily. In some elderly patients initial treatment with one capsule of Madopar 62.5 once or twice daily, increasing by one capsule every third or fourth day may suffice. Patients who experience fluctuations in response may also benefit from administration of smaller more frequent doses using Madopar 62.5.

Contra-indications
Narrow-angle glaucoma, severe psychoneuroses or psychoses. It should not be given in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal, or to patients under 25 years of age, to pregnant women, or to patients who have a history of, or who may be suffering from, a malignant melanoma.

Precautions
Drugs which interfere with central amine mechanisms should be avoided: Endocrine, renal, pulmonary or cardiovascular disease, hepatic disorder, peptic ulcer, osteoporosis, sympathomimetic drugs, antihypertensive drugs. Patients who improve on Madopar therapy should be advised to resume normal activities gradually as rapid mobilisation may increase the risk of injury.

Side-effects
Nausea and vomiting, cardiovascular disturbances, psychiatric disturbances, involuntary movements.

Packaging
Madopar 62.5 capsules, Madopar 125 capsules and Madopar 250 capsules in packings of 100

Licence Numbers
0031/0125 (Madopar 62.5 capsules); 0031/0073 (Madopar 125 capsules); 0031/0074 (Madopar 250 capsules)

Basic NHS Cost
Madopar capsules 62.5 £4.01 per 100
Madopar capsules 125 £7.23 per 100
Madopar capsules 250 £12.94 per 100

Roche Products Limited
PO Box 8
Welwyn Garden City
Hertfordshire AL7 3AY

Madopar is a trade mark.

the original 4+1 combination in three dosage forms, 62.5, 125 and 250
'Sinemet-Plus' contains 100 mg of levodopa and 25 mg of carbidopa. 'Sinemet-Plus' provides a low dose of levodopa together with sufficient carbidopa to inhibit effectively peripheral dopa-decarboxylase in many patients. It retains the advantage of co-prescribing carbidopa and levodopa by reducing or eliminating certain levodopa side effects, e.g. GI upsets, etc.

Therefore 'Sinemet-Plus' is an effective low level introduction to levodopa therapy for:

☐ patients on anticholinergics requiring 'add on' levodopa therapy
☐ first-time patients requiring low levels of levodopa
☐ patients with a low levodopa tolerance to allow relatively higher levels of carbidopa

The addition of 'Sinemet-Plus' to the 'Sinemet' range means that Parkinsonian patients may benefit from levodopa therapy earlier and be eased more gradually into the full-scale therapy offered by Sinemet® 110 and Sinemet® 275.

SINEMET-Plus
A NEW START FOR MANY PARKINSONIAN PATIENTS

For prescribing information, see overleaf.
PREScribing INFORMATION

INDICATIONS
For treatment of Parkinson's disease and syndrome.

DOsAGE AND ADMINISTRATION
The optimum daily dosage of 'Sinemet' must be determined by careful titration for each patient. 'Sinemet' tablets are available as:
- 'Sinemet' 100 containing 10 mg carbidopa and 100 mg levodopa.
- 'Sinemet-Plus' containing 25 mg carbidopa and 100 mg levodopa.
- 'Sinemet' 275 containing 25 mg carbidopa and 250 mg levodopa.

General considerations: Studies show that the peripheral enzyme dopa decarboxylase is fully inhibited (saturated) by carbidopa at doses between 70 and 100 mg a day. The formulations of 'Sinemet' are designed to provide a range of doses with sufficient carbidopa to inhibit peripheral dopa decarboxylase and thus exert optimal therapy.

Patients who require less than 700 mg levodopa given as 'Sinemet' 275 will theoretically not receive sufficient carbidopa to saturate peripheral dopa decarboxylase. 'Sinemet-Plus' may be helpful, especially for patients with nausea and vomiting.

Most patients can be maintained on divided doses of three to six tablets of 'Sinemet' 275 a day. Tablets are scored for easy division should the frequency of daily dosage need to be increased. During the titration period, 'Sinemet-Plus' may be more convenient.

Patients on 'Sinemet-Plus' who need a higher dosage should be switched to 'Sinemet' 275. Dosage with either form should not exceed eight tablets a day if patients do show a need for higher doses, levodopa should be added.

Because both beneficial and adverse effects are seen more rapidly with 'Sinemet' than with levodopa, patients should be carefully monitored during the dosing adjustment period. Unvoluntary movements, particularly blepharospasm, is a useful early sign of excess dosage in some patients.

'Sinemet' 100 can be used as an alternative to 'Sinemet-Plus'.

Patients not receiving levodopa: Dosage may be initiated with one tablet of 'Sinemet-Plus' three times a day, and adjusted as necessary by small increments to a maximum daily dosage of eight tablets. If patients need more levodopa, one tablet of 'Sinemet' 275 should be substituted three or four times a day. If further titration is necessary, the dosage of 'Sinemet' 275 may be increased gradually to a maximum of eight tablets a day.

Patients receiving levodopa: Discontinue levodopa at least twelve hours (24 hours for slow-release preparations) before starting therapy with 'Sinemet'. The easiest way to do this is to give 'Sinemet' as the first morning dose after a night without any levodopa. The dose of 'Sinemet' should be approximately 20% of the previous daily dosage of levodopa.

The suggested starting dose for most patients is one tablet of 'Sinemet' 275 three or four times a day.

Patients requiring less than 1,500 mg levodopa a day should be started on one tablet of 'Sinemet-Plus' three or four times a day.

The dosage may then be adjusted gradually, but should not exceed eight tablets a day.

Patients receiving levodopa with another decarboxylase inhibitor: When transferring a patient to 'Sinemet' from levodopa combined with another decarboxylase inhibitor, its dosage should be discontinued at least twelve hours before 'Sinemet' is started. Begin with a dosage of 'Sinemet' that will provide the same amount of levodopa as contained in the other levodopa decarboxylase inhibitor combination.

Use with other antiparkinsonian agents: Current evidence indicates that other antiparkinsonian agents such as anticholinergics and amantadine may be continued when 'Sinemet' is introduced, although dosage may have to be adjusted.

CONTRA-INDICATIONS
Concurrent use with monoamine oxidase inhibitors (these must be discontinued at least two weeks before starting 'Sinemet'); narrow-angle glaucoma; known hypersensitivity to this medication. Because levodopa may activate a malignant melanoma, it should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.

See also 'Use in pregnancy and the nursing mother', under 'Precautions'.

PRECAUTIONS
'Sinemet' is not recommended for the treatment of drug-induced extrapyramidal reactions. 'Sinemet' should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease. All patients should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antipsychotic behaviour. Patients with current psychoses should be treated with caution. Patients with a history of severe involuntary movements or psychotic episodes when treated with levodopa alone should be observed carefully when 'Sinemet' is substituted. These reactions are thought to be due to increased bram dopamine following administration of levodopa, and use of 'Sinemet' may cause a recurrence. If concomitant administration of psychoactive drugs such as phenothiazines or butyrophenones is necessary, such drugs should be administered with caution, and patients carefully observed for loss of antiparkinsonian effect. Patients with a history of convulsions should be treated with caution. Both phenytoin and papaverine have been reported to reverse the beneficial effects of levodopa.

Patients with chronic wide-angle glaucoma may be treated cautiously with 'Sinemet'. Provided the intraocular pressure is well controlled and the patient monitored carefully for changes in intraocular pressure during therapy.

Care should be exercised when 'Sinemet' is administered to patients with a history of myocardial infarction who have atrial, nodal, or ventricular arrhythmias. Cardiac function should be monitored with particular care in such patients during the period of initial dosage adjustment.

As symptoms of postural hypotension have occasionally been reported, 'Sinemet' should be given with caution to patients receiving antihypertensive agents. Adjustment of the dosage of the antihypertensive agent may be required when 'Sinemet' is started. (For patients on pargyline, see the contra-indication on monoamine oxidase inhibitors.)

As with levodopa there is a possibility of upper gastrointestinal haemorrhage in patients with a history of peptic ulcer disease.

If general anaesthesia is required, therapy with 'Sinemet' may be continued as long as the patient is permitted to take fluids and medication by mouth. If therapy is interrupted temporarily, the usual daily dosage may be administered as soon as the patient is able to take oral medication.

Transient abnormalities in laboratory test results may occur, but have not been associated with clinical evidence of disease. These include elevated levels of blood urea, SCOT, SGPT, LDH, bilirubin, alkaline phosphatase, or protein-bound iodine.

Positive Coombs tests have been reported, both with 'Sinemet' and levodopa alone, but haemolytic anaemia is extremely rare.

Use in children: The safety of 'Sinemet' in patients under eighteen years of age has not been established.

Use in pregnancy and the nursing mother: Although the effects of 'Sinemet' on human pregnancy and lactation are unknown, both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. Therefore, use of 'Sinemet' in women of childbearing potential requires that the anticipated benefits of the drug be weighed against possible hazards should pregnancy occur. 'Sinemet' should not be given to nursing mothers.

Drug interactions: Clinical experience with concurrent administration of 'Sinemet' and other standard antiparkinsonian drugs, e.g. benztriptine mesylate, benzhexol hydrochloride, is limited. To date, however, there has been no indication of interactions that would preclude concurrent use. No adverse reactions have been reported that do not occur with the various agents alone.

SIDE EFFECTS
Side effects that occur frequently with 'Sinemet' are those due to the central neurophysiological activity of dopamine. These reactions can usually be diminished by dosage reduction. The most common are choreiform, dystonic, and other involuntary movements. Muscle twitching and blepharospasm may be taken as early signs to consider dosage reduction.

Less common are mental changes, including paranoid
Neuromuscular Diseases

A Practical Approach to Diagnosis and Management

Michael Swash, Consultant Neurologist, The London Hospital, Senior Lecturer in Neuropathology, The London Hospital Medical College
Martin S. Schwartz, Consultant Clinical Neuropathologist, Atkinson Morley's Hospital, London.

This book represents a new approach to neuromuscular diseases. The investigation and management of these disorders is complex, necessitating a multidisciplinary approach, and this has led to fragmentation of information about the clinical, electrophysiological and pathological features of these diseases. In this book, written by two neurologists with experience in both neuropathology and clinical neurophysiology, a comparative presentation of these clinical and investigative data is used. This holistic approach allows the relevance of these different diagnostic methods, and the changes apparent at different stages in the disease or in its treatment, to be more easily understood.

This book will thus be of particular value to all those involved in the diagnosis and management of these disorders, and for those in training. Since neuromuscular disorders are common the book will be useful to most clinicians, providing as it does a source of information about these disorders, their investigation, and their management.

1981. 167 figures, XXII, 316 pages.
Cloth DM 110,—; approx. US$51.20 approx. £ 26.50
ISBN 3-540-10548-4

Springer-Verlag
Berlin
Heidelberg
New York
For many grand mal patients

a full, normal life under the protection of

Epilim®

sodium valproate

200 enteric-coated, 500 enteric-coated tablets; syrup.
Epilim is a powerful anticonvulsant capable of providing control for the majority of adults with tonic-clonic seizures or other epilepsies, including those not well controlled on previous treatments. Because it controls without sedation, Epilim allows many patients to lead full, normal lives.

Hyperammonemia without hepatic damage can occur in patients during treatment with valproic acid or sodium valproate. This may manifest clinically as vomiting, ataxia and increasing clouding of consciousness. Should these symptoms occur, Epilim should be discontinued.

Valproic acid inhibits second stage of platelet aggregation. Reversible prolongation of bleeding time and thrombocytopenia have been reported. Spontaneous bruising or bleeding is an indication for withdrawal of treatment pending investigations. Patients receiving Epilim should be monitored for platelet function before major surgery. Renal cell hypoplasia and leucopenia have been reported. The blood picture returned to normal when the drug was discontinued. Pancreatitis has occurred in patients receiving valproic acid or sodium valproate. Patients experiencing acute abdominal pain should have serum amylase estimated.

Minor gastric irritation and, less frequently, nausea may occur at the start of treatment but these problems can usually be overcome by administering Epilim tablets or syrup with or after food, or by transcribing the patient to the Epilim enteric-coated formulations. Transient hair loss has been noted in some patients. Regrowth normally begins within six months. Tremor has occasionally been observed at high dosage. Oedema has been reported. Increase in alertness, appetite and weight may occur. Combined medication: Epilim is generally well tolerated in combination with other anti-epileptic agents; however, as interaction occurs between these compounds, it may sometimes be necessary to reduce the dosage of other drugs when adding Epilim to existing anti-convulsant therapy. Epilim may also potentiate the effect of monoamine oxidase inhibitors and other anti-depressants and dosage of such compounds should be reduced.

Diabetic patients: Epilim may give false positives in urine testing for ketones. Care should be taken when treating diabetic patients with Epilim syrup which contains 3.6g sucrose per 5ml.

Women of childbearing age: Valproic acid or sodium valproate, like certain other anti-convulsants, have been shown to be teratogenic in animals. In women of childbearing age, the benefits of these compounds should be weighed against the possible hazard suggested by these findings.

Further Information:
When plasma valproic acid levels within the recommended range of 50–100μg/ml (350–840μmol/l) and serum albumin levels are normal, about 90% of the drug is bound to albumin. If the total plasma valproic acid rises above the upper range of normal, or if there is a hypoalbuminaemia, the percentage of free valproic acid may rise markedly in disproportion to any dosage increase and may be associated with a higher incidence of adverse effects.

Product Licence Numbers, Names and Addresses:
Epilim 200 enteric-coated tablets 0623/0006
Epilim Tablets 0623/0001
Epilim Tablets 0623/0005
Epilim Syrup 0623/0004

NHS Cost:
Epilim 200 enteric-coated tablets: 100.57.04
Epilim 500 enteric-coated tablets: 100.57.60
Epilim Syrup 200ml: 64.03
Epilim 200mg tablets: 100.55.45

Additional information is available from LABAZ: Sanofi U.K. Ltd. Regent House, Heaton Lane, Stockport SK4 1AG, Cheshire.
Telephone: 061-480 0995/6.7/8
Micra-fine
A New Range of Fine Microsurgical Titanium Instruments specifically designed for a wide range of procedures including micro-anastomosis

Developed jointly by Downs Surgical and Micra from the original Microsurgical Instruments designed by Dermot Pierse

This new range of instruments is ideally suited to all types of microsurgery and especially suitable for the anastomosis of very small vessels. Therefore there are applications in Microvascular Surgery, Plastic Surgery (e.g. replanting digits), Gynaecology (e.g. repair of fallopian tubes), Urology (e.g. reversal of vasectomy), Neurosurgery, Orthopaedic Surgery, Hand Surgery and all other fine surgical procedures performed under the microscope, with telescopic loupes or with simple binocular loupes.

Manufactured in Titanium
The particular metallurgical properties of titanium make it the ideal material for fine surgical instruments. Titanium instruments are non-magnetic, lighter weight, have greater strength and are longer lasting than conventional stainless steel micro surgical instruments. The blue titanium oxide finish minimises the light reflection under the microscope.

Downs Surgical
A major new edition...

TEXTBOOK OF EPILEPSY
Edited by John Laidlaw and Alan Richens
1982 416 pages illus hardback £27.00 ISBN 0 443 02039 6
A comprehensive and up-to-date account of the diagnosis and treatment of epilepsy.
This edition has been considerably revised and expanded, and now includes contributions from eminent authorities in the USA, Canada, Denmark, Sweden, France and Italy, in addition to the United Kingdom, giving a more international perspective on the subject.
Reviews of the first edition include:
'...an excellent summary of present-day knowledge...' Lancet
'...this excellent book can and should be read in its entirety...' Journal of Neurology, Neurosurgery & Psychiatry

Volume 3 in the series
Clinical Neurology and Neurosurgery Monographs

EVOLED POTENTIALS IN CLINICAL TESTING
Edited by A.M. Halliday
1981 800 pages 253 line illus & 5 half-tones hardback £15.00 approx ISBN 0 443 01791 3
This book, edited by one of the key figures in the field, provides the sort of information which will be useful to all those setting up an evoked potential (EP) service for the first time.
Each chapter covers the use of EP recordings in a specific field, and has been written by an acknowledged authority familiar with their use in a day to day setting.

New book...

CHEMISMS OF THE BRAIN
BASIC AND APPLIED NEUROCHEMISTRY
Edited by Richard Rodnight, Herman S. Bachelard & William L. Stahl
1981 348 pages 20 half-tone & 69 line illus hardback £25.00 ISBN 0 443 02409 X

Commemorative volume...

EPILEPSY AND PSYCHIATRY
Edited by E.H. Reynolds and M.R. Trimble
1981 400 pages 10 half-tone & 2 line illus hardback £22.00 ISBN 0 443 02311 5
The publication of this book commemorates the centenary of the classic work by Sir William Gowers—'Epilepsy and Other Chronic Convulsive Diseases', which was published by Churchill in 1881.

New volume...

RECENT ADVANCES IN CLINICAL NEUROLOGY - 3
Edited by W.B. Matthews and Gilbert H. Glaser
1981 264 pages 24 half-tone & 10 line illus paperback £11.00 ISBN 0 443 02121 X ISSN 0307 7403

Churchill Livingstone
Robert Stevenson House, 1-3 Baxter's Place, Leith Walk, Edinburgh EH1 3AF, UK